These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23763530)

  • 21. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians.
    Coley CM; Barry MJ; Fleming C; Fahs MC; Mulley AG
    Ann Intern Med; 1997 Mar; 126(6):468-79. PubMed ID: 9072935
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prostate Specific Antigen (PSA), yet how much damage?].
    Braillon A; Hill C; Dubois G
    Presse Med; 2012 May; 41(5):482-5. PubMed ID: 22336482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
    Drazer MW; Huo D; Eggener SE
    J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
    JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer.
    Shteynshlyuger A; Andriole GL
    J Urol; 2011 Mar; 185(3):828-32. PubMed ID: 21239021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate Cancer Screening and the Associated Controversy.
    Tabayoyong W; Abouassaly R
    Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Prostate-specific Antigen (PSA) Screening Trials and Revised PSA Screening Guidelines on Rates of Prostate Biopsy and Postbiopsy Complications.
    Gershman B; Van Houten HK; Herrin J; Moreira DM; Kim SP; Shah ND; Karnes RJ
    Eur Urol; 2017 Jan; 71(1):55-65. PubMed ID: 26995328
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Welch HG; Albertsen PC
    J Natl Cancer Inst; 2009 Oct; 101(19):1325-9. PubMed ID: 19720969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline prostate-specific antigen testing at a young age.
    Loeb S; Carter HB; Catalona WJ; Moul JW; Schroder FH
    Eur Urol; 2012 Jan; 61(1):1-7. PubMed ID: 21862205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for prostate cancer: the current evidence and guidelines controversy.
    Gomella LG; Liu XS; Trabulsi EJ; Kelly WK; Myers R; Showalter T; Dicker A; Wender R
    Can J Urol; 2011 Oct; 18(5):5875-83. PubMed ID: 22018148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.
    Kim SP; Karnes RJ; Gross CP; Meropol NJ; Van Houten H; Abouassaly R; Shah ND
    Urology; 2016 Nov; 97():111-117. PubMed ID: 27527411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.
    Squiers LB; Bann CM; Dolina SE; Tzeng J; McCormack L; Kamerow D
    Am J Prev Med; 2013 Aug; 45(2):182-9. PubMed ID: 23867025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society.
    Littrup PJ
    Cancer; 1997 Nov; 80(9):1864-70. PubMed ID: 9351561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The socioeconomic implications of prostate-specific antigen screening.
    Benoit RM; Naslund MJ
    Urol Clin North Am; 1997 May; 24(2):451-8. PubMed ID: 9126243
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness Analysis of Prostate-Specific Antigen Screening Among Chinese Men.
    Zhao G; Shao Y; Zhang N; Wang J; Yuan L; Sun X; Shi L
    Value Health Reg Issues; 2020 May; 21():272-279. PubMed ID: 32402819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening.
    Porter MP; Stanford JL; Lange PH
    Prostate; 2006 Jul; 66(10):1044-51. PubMed ID: 16598738
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?
    Crawford ED; Abrahamsson PA
    Eur Urol; 2008 Aug; 54(2):262-73. PubMed ID: 18556114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PSA testing for men at average risk of prostate cancer.
    Armstrong BK; Barry MJ; Frydenberg M; Gardiner RA; Haines I; Carter SM
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Socioeconomic advantages of longer screening intervals for men with low prostate-specific antigen levels in prostate cancer mass screening].
    Kobayashi T; Goto R; Hinotsu S; Ogawa O
    Hinyokika Kiyo; 2013 Mar; 59(3):159-66. PubMed ID: 23633630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.